Biosergen is a synthetic biology company developing drugs using biosynthetic engineering and natural products that is headquartered in Trondheim, Norway and was founded in 2004 by Anders Kronström. The company was founded based on the potential of synthetic biology inventions for the bioengineering of products combined with chemical synthesis made at the Norwegian University of Science and Technology (NTNU) and SINTEF.
On September 1, 2017 Peder M. Anderson became the CEO of Biosergen, replacing the CEO and founder Anders Kronström.
On February 12, 2016 Biosergen received a grant for the BIA innovation reward from the Research Council of Norway. Biosergen was one on 50 companies awarded the grant. At the time of funding the CEO of Biosergen, Anders Kronström, made the following comment regarding the grant funding:
This innovation grant means a lot for our research and also for patients worldwide suffering from diseases caused by systemic fungal infections. It will directly strengthen our opportunities to turn our innovation efforts into improved treatments.